Tagged with UK

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

UK Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on the UK life sciences landscape.   One of the key matters for us is that we don’t have direct customers.…

UK Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia research, care and diagnosis; and the enduring importance of international collaboration.   In the UK, when people want to help…

India Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’ time by adding more cost-effective and highly effective dosage forms to their strong product portfolio. Can you briefly introduce your…

Switzerland Cristina Marti’s colorful and successful career has taken her across Asia from Spain, before settling in Switzerland with Indukern. In this interview, Marti explores themes of competition in Switzerland, the differences in global markets and why Indukern Switzerland and other API sourcing firms are a reliable route to understanding market…

UK UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam from London following Brexit. Following the Brexit vote, the UK is already seeing problems in filling senior positions at life…

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…

Ukraine Healthcare expenditure as a share of GDP has shrunk dramatically in Ukraine since 2013. Hospitals bear the brunt of primary care in Ukraine. WHO standards require a far greater role for family doctors within the overall healthcare system. Life expectancy in Ukraine lags behind that of its neighbors and peers.…

Ukraine The Top 30 companies in Ukraine based on 2016 sales. Homegrown hero Farmak leads the way, with USD 88 million in sales for the year. French company Sanofi follows in second place.

Ukraine Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces criticism from domestic players. “Healthcare procurement was widely considered as one of the areas most seriously altered by corruption” Tetiana…

Tunisia Haithem Boukhari, CEO of medtech manufacturer Boukhari Prince Médical, documents the favorable business environment in Tunisia that has allowed him to grow the company’s production site tenfold in the last 15 years, as well as its Middle Eastern and South American ambitions. What are Boukhari Prince Medical’s main activities? “Boukhari…

UK Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving the European Atomic Energy Community (Euratom) on cancer care in the UK. “The UK relies on Euratom for the diagnosis…